Although combination therapy with GVAX and CTLA-4 blockade increases tumor antigen-specific CD8 T cell proliferation and activation, this has not been consistently shown to correspond with tumor eradication or improved survival [42], so we used tumor score and weight of the genital tract as direct measures of effectiveness in a relevant preclinical model. The gene discussed is CTLA4; the disease is neoplasm.